Immune checkpoint inhibitor-related hypophysitis
- 6 May 2022
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 36 (3) , 101668
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking AntibodyScience Translational Medicine, 2014
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institutionEndocrine-Related Cancer, 2014
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2013
- Endocrine Side Effects Induced by Immune Checkpoint InhibitorsThe Journal of Clinical Endocrinology & Metabolism, 2013
- Adult combined GH, prolactin, and TSH deficiency associated with circulating PIT-1 antibody in humansJournal of Clinical Investigation, 2011
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 BlockadeClinical Cancer Research, 2007
- Autoimmune HypophysitisEndocrine Reviews, 2005
- Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeProceedings of the National Academy of Sciences, 2002
- Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytesInternational Immunology, 1996
- A new member of the immunoglobulin superfamily—CTLA-4Nature, 1987